I agree that this site is using cookies. You can find further informations here.
X
Kling, Douglas
67  results:
Search for persons X
?
1

Obicetrapib as an Adjunct to Stable Statin Therapy in Japan..:

Harada-Shiba, Mariko ; Davdison, Michael H. ; Ditmarsch, Marc...
Journal of Atherosclerosis and Thrombosis.  , 2024
Link: https://doi.org/10.5551/..
 
?
2

Obicetrapib on top of maximally tolerated lipid‐modifying t..:

Nicholls, Stephen J. ; Nelson, Adam J. ; Ditmarsch, Marc...
American Heart Journal.  274 (2024)  - p. 32-45 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Guiding Dyslipidemia Treatment: A Population Pharmacokineti..:

Dunn, Allison ; Ditmarsch, Marc ; Kastelein, John J. P....
The Journal of Clinical Pharmacology.  , 2024
Link: https://doi.org/10.1002/..
 
?
4

Obicetrapib plus ezetimibe as an adjunct to high-intensity ..:

Ballantyne, Christie M. ; Ditmarsch, Marc ; Kastelein, John JP...
Journal of Clinical Lipidology.  17 (2023)  4 - p. 491-503 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Lipid lowering effects of the CETP inhibitor obicetrapib in..:

Nicholls, Stephen J. ; Ditmarsch, Marc ; Kastelein, John J....
Nature Medicine.  28 (2022)  8 - p. 1672-1678 , 2022
Link: https://doi.org/10.1038/..
 
?
6

Obicetrapib Lowers LDL-C in Patients Taking High Intensity ..:

Kling, Douglas
Journal of Clinical Lipidology.  16 (2022)  3 - p. e73 , 2022
Link: https://doi.org/10.1016/..
 
?
7

Obicetrapib Lowers LDL-C in Patients Taking High Intensity ..:

Ditmarsch, Marc ; Kling, Douglas ; Curcio, Danielle...
Journal of Clinical Lipidology.  16 (2022)  3 - p. e67-e68 , 2022
Link: https://doi.org/10.1016/..
 
?
8

IL-6 inhibition with ziltivekimab in patients at high ather..:

Ridker, Paul M ; Devalaraja, Matt ; Baeres, Florian M M...
The Lancet.  397 (2021)  10289 - p. 2060-2069 , 2021
Link: https://doi.org/10.1016/..
 
?
9

Effects of omega-3 carboxylic acids on lipoprotein particle..:

Dunbar, Richard L. ; Nicholls, Stephen J. ; Maki, Kevin C....
Lipids in Health and Disease.  14 (2015)  1 - p. , 2015
Link: https://doi.org/10.1186/..
 
?
10

Omega-3 free fatty acids for the treatment of severe hypert..:

Kastelein, John J.P. ; Maki, Kevin C. ; Susekov, Andrey...
Journal of Clinical Lipidology.  8 (2014)  1 - p. 94-106 , 2014
Link: https://doi.org/10.1016/..
 
?
11

On-Treatment Triglyceride Concentration is a Determinant of..:

Maki, Kevin C. ; Kling, Douglas ; Dicklin, Mary R..
Journal of Clinical Lipidology.  8 (2014)  3 - p. 342 , 2014
Link: https://doi.org/10.1016/..
 
?
12

Plasma Fatty Acids as Predictors of Triglyceride and Non-HD..:

Maki, Kevin C. ; Dicklin, Mary R. ; Schild, Arianne L...
Journal of Clinical Lipidology.  8 (2014)  3 - p. 341-342 , 2014
Link: https://doi.org/10.1016/..
 
?
13

Steady-state bioavailability of prescription omega-3 on a l..:

Offman, Elliot ; Marenco, Ted ; Ferber, Sandy...
Vascular Health and Risk Management.  , 2013
Link: https://doi.org/10.2147/..
 
?
14

A Highly Bioavailable Omega-3 Free Fatty Acid Formulation I..:

Maki, Kevin C. ; Orloff, David G. ; Nicholls, Stephen J....
Clinical Therapeutics.  35 (2013)  9 - p. 1400-1411.e3 , 2013
Link: https://doi.org/10.1016/..
 
?
15

Epanova Lowers Apolipoprotein C-III and Increases LDL-Parti..:

Maki, Kevin Carl ; Orloff, David ; Nicholls, Stephen...
Journal of Clinical Lipidology.  7 (2013)  3 - p. 269 , 2013
Link: https://doi.org/10.1016/..
 
1-15